慢性阻塞性肺疾病患者应用莫西沙星治疗的疗效及预后分析
|
摘要
目的 :探讨慢性阻塞性肺疾病(COPD)患者应用莫西沙星治疗后的疗效以及对患者预后的影响。方法 :选取2015年3月～2016年6月在我院接受治疗的慢性阻塞性肺疾病患者100例,采用随机数表法将患者分为两组,观察组(n=50)和对照组(n=50)。对照组患者给予左氧氟沙星治疗,观察组患者给予莫西沙星治疗。比较治疗后的临床效果,记录患者治疗前、治疗后WBC(白细胞计数)、NBC(中性粒细胞)、CRP(超敏C反应蛋白)、PaO_2(血氧分压)以及PaCO_2(二氧化碳分压)变化,比较并发症发生率。结果 :治疗后,观察组总有效率96.00%高于对照组78.00%。治疗后,患者的WBC、NBC以及CRP均有降低,观察组(6.12±1.56*10~9.L~(-1)、59.12±10.45%、20.45±5.02mg/L)低于对照组(8.20±2.14*10~9.L~(-1)、64.78±9.56%、29.12±8.99mg/L);治疗后,患者的PaO_2均升高,观察组高于对照组。患者均有出现皮肤瘙痒、失眠以及恶心等并发症,观察组总发生率12.00%低于对照组30.00%。结论 :给予COPD患者莫西沙星治疗,能够有效缓解患者的呼吸困难,改善患者的肺部功能,降低气道阻力,并发症少,是一种安全有效的治疗方法,值得临床推广使用。
Objective To investigate the efficacy and prognosis of moxifloxacin in the treatment of chronic obstructive pulmonary disease(COPD). Methods 100 cases of patients with chronic obstructive pulmonary disease from March 2015 to June 2016 in our hospital, all patients were randomly divided into two groups, observation group(n=50) and control group(n=50). The patients in the control group were treated with levofloxacin, and the patients in the observation group were treated with moxifloxacin. The clinical effect after treatment were compared before and after treatment WBC(white blood cell count) and NBC(neutrophils), CRP(high sensitivity C reactive protein(PaO_2), partial pressure of oxygen(PaCO_2) and carbon dioxide partial pressure) changes were recorded and the complication rate were compared. Results After treatment, the total effective rate of the observation group was 96%higher than that of the control group(78%). After treatment, the levels of WBC, NBC and CRP were all decreased. The observation group(6.12 + 1.56*10~9. L~(-1), 59.12 + 10.45%, 20.45 + 5.02 mg/L) was lower than that of the control group(8.20 + 2.14*10~9. L~(-1),64.78 + 9.56%, 29.12 + 8.99 mg/L). and After treatment, the PaO_2 of the patients increased and the observation group was higher than that of the control group. The patients had complications such as skin pruritus, insomnia and nausea, and the total incidence of the observation group was 12% lower than that of the control group(30%). Conclusion Moxifloxacin treatment in patients with chronic obstructive pulmonary disease(COPD) can improve the efficacy and prognosis of moxifloxacin treatment.
Objective To investigate the efficacy and prognosis of moxifloxacin in the treatment of chronic obstructive pulmonary disease(COPD). Methods 100 cases of patients with chronic obstructive pulmonary disease from March 2015 to June 2016 in our hospital, all patients were randomly divided into two groups, observation group(n=50) and control group(n=50). The patients in the control group were treated with levofloxacin, and the patients in the observation group were treated with moxifloxacin. The clinical effect after treatment were compared before and after treatment WBC(white blood cell count) and NBC(neutrophils), CRP(high sensitivity C reactive protein(PaO_2), partial pressure of oxygen(PaCO_2) and carbon dioxide partial pressure) changes were recorded and the complication rate were compared. Results After treatment, the total effective rate of the observation group was 96%higher than that of the control group(78%). After treatment, the levels of WBC, NBC and CRP were all decreased. The observation group(6.12 + 1.56*10~9. L~(-1), 59.12 + 10.45%, 20.45 + 5.02 mg/L) was lower than that of the control group(8.20 + 2.14*10~9. L~(-1),64.78 + 9.56%, 29.12 + 8.99 mg/L). and After treatment, the PaO_2 of the patients increased and the observation group was higher than that of the control group. The patients had complications such as skin pruritus, insomnia and nausea, and the total incidence of the observation group was 12% lower than that of the control group(30%). Conclusion Moxifloxacin treatment in patients with chronic obstructive pulmonary disease(COPD) can improve the efficacy and prognosis of moxifloxacin treatment.
引文
[1]林其昌,刘凯雄,刘少滨,等.莫西沙星治疗慢性阻塞性肺疾病急性加重疗效和安全性的多中心研究[J].中华结核和呼吸杂志,2015, 38(5):366-369.
[2]李锋,张翼,尤慧敏,等.莫西沙星溶液雾化吸入对慢性阻塞性肺疾病合并呼吸衰竭患者炎症介质及血气分析指标的影响[J].中国生化药物杂志, 2015, 35(10):110-112.
[3]张福红,王英,魏铁垒,等.美罗培南联合莫西沙星治疗慢性阻塞性肺疾病并发感染性肺炎患者肺部状态及炎性应激的影响研究[J].中华医院感染学杂志, 2016, 26(23):5416-5417, 5479.
[4]Glaser JB, Pau D, Maniatis T. Differential Risk Factors for Chronic Obstructive Pulmonary Disease 30-Day Readmissions According to Indication for Readmission[J]. Ann Am Thorac Soc, 2016, 13(3):447.
[5]张海英,王新卫,刘新年,等. CT引导下经皮肺穿刺与纤维支气管镜在慢性阻塞性肺疾病中的诊断价值分析[J].湖南师范大学学报(医学版), 2015, 12(02):45-48.
[6]陈旭波,徐晓雯,韩志青,等.清金化痰汤治疗慢性阻塞性肺疾病急性加重期临床观察[J].世界中医药, 2014, 9(06):743-746.
[7]覃勇民,韦庆,韦美英,等.莫西沙星雾化吸入对慢性阻塞性肺疾病合并呼吸衰竭患者用力肺活量和用力呼气量及最大呼气流速的影响研究[J].实用心脑肺血管病杂志, 2016, 24(z1):50-51.
[8]武光瑞.慢性阻塞性肺疾病急性加重期应用莫西沙星和左氧氟沙星治疗的效果和安全性分析[J].中国医院统计, 2016, 37(12):2991-2992.
[9]齐慧生,刘宝欣,郭红,等.美罗培南联合莫西沙星治疗慢性阻塞性肺疾病感染性肺炎的疗效与安全性研究[J].中华医院感染学杂志, 2016, 26(9):1967-1969.
[10]兰雪云.解决问题技能干预对提高慢性阻塞性肺疾病患者生活质量的影响[J].中国健康心理学杂志, 2014, 22(04):599-601.
[11]冼少静,石湘淋,黄奕江.慢性阻塞性肺疾病伴呼吸衰竭患者两种通气模式应用比较研究[J].湖南师范大学学报(医学版), 2016,13(03):80-82.
[12]陈勇,王赛斌.舒利迭联合无创通气治疗老年急性加重期慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的疗效[J].中国医院统计, 2015,23(16):4593-4594.
[2]李锋,张翼,尤慧敏,等.莫西沙星溶液雾化吸入对慢性阻塞性肺疾病合并呼吸衰竭患者炎症介质及血气分析指标的影响[J].中国生化药物杂志, 2015, 35(10):110-112.
[3]张福红,王英,魏铁垒,等.美罗培南联合莫西沙星治疗慢性阻塞性肺疾病并发感染性肺炎患者肺部状态及炎性应激的影响研究[J].中华医院感染学杂志, 2016, 26(23):5416-5417, 5479.
[4]Glaser JB, Pau D, Maniatis T. Differential Risk Factors for Chronic Obstructive Pulmonary Disease 30-Day Readmissions According to Indication for Readmission[J]. Ann Am Thorac Soc, 2016, 13(3):447.
[5]张海英,王新卫,刘新年,等. CT引导下经皮肺穿刺与纤维支气管镜在慢性阻塞性肺疾病中的诊断价值分析[J].湖南师范大学学报(医学版), 2015, 12(02):45-48.
[6]陈旭波,徐晓雯,韩志青,等.清金化痰汤治疗慢性阻塞性肺疾病急性加重期临床观察[J].世界中医药, 2014, 9(06):743-746.
[7]覃勇民,韦庆,韦美英,等.莫西沙星雾化吸入对慢性阻塞性肺疾病合并呼吸衰竭患者用力肺活量和用力呼气量及最大呼气流速的影响研究[J].实用心脑肺血管病杂志, 2016, 24(z1):50-51.
[8]武光瑞.慢性阻塞性肺疾病急性加重期应用莫西沙星和左氧氟沙星治疗的效果和安全性分析[J].中国医院统计, 2016, 37(12):2991-2992.
[9]齐慧生,刘宝欣,郭红,等.美罗培南联合莫西沙星治疗慢性阻塞性肺疾病感染性肺炎的疗效与安全性研究[J].中华医院感染学杂志, 2016, 26(9):1967-1969.
[10]兰雪云.解决问题技能干预对提高慢性阻塞性肺疾病患者生活质量的影响[J].中国健康心理学杂志, 2014, 22(04):599-601.
[11]冼少静,石湘淋,黄奕江.慢性阻塞性肺疾病伴呼吸衰竭患者两种通气模式应用比较研究[J].湖南师范大学学报(医学版), 2016,13(03):80-82.
[12]陈勇,王赛斌.舒利迭联合无创通气治疗老年急性加重期慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的疗效[J].中国医院统计, 2015,23(16):4593-4594.